The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11111 malaria professionals are enjoying the free benefits of MalariaWorld today

TACT

To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies

September 1, 2021 - 17:12 -- Open Access
Author(s): 
de Haan F, Bolarinwa OA, Amaratunga C, et al.
Reference: 
PLoS One. 2021 Aug 31;16(8):e0256567

Triple artemisinin-based combination therapies (TACTs) are being developed as a response to artemisinin and partner drug resistance in the treatment of falciparum malaria in Southeast Asia. In African countries, where current artemisinin-based combination therapies (ACTs) are still effective, TACTs have the potential to benefit the larger community and future patients by mitigating the risk of drug resistance. This study explores the extent to which the antimalarial drug markets in African countries are ready for a transition to TACTs.

Toward New Transmission-Blocking Combination Therapies: Pharmacokinetics of 10-Amino-Artemisinins and 11-Aza-Artemisinin and Comparison with Dihydroartemisinin and Artemether

August 4, 2021 - 16:26 -- Open Access
Author(s): 
Daniel J Watson, Lizahn Laing, Liezl Gibhard, Ho Ning Wong, Richard K Haynes, Lubbe Wiesner
Reference: 
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0099021

As artemisinin combination therapies (ACTs) are compromised by resistance, we are evaluating triple combination therapies (TACTs) comprising an amino-artemisinin, a redox drug, and a third drug with a different mode of action. Thus, here we briefly review efficacy data on artemisone, artemiside, other amino-artemisinins, and 11-aza-artemisinin and conduct absorption, distribution, and metabolism and excretion (ADME) profiling in vitro and pharmacokinetic (PK) profiling in vivo via intravenous (i.v.) and oral (p.o.) administration to mice.

Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations

March 3, 2021 - 15:45 -- Open Access
Author(s): 
Paulina Tindana, Freek de Haan, Chanaki Amaratunga, Mehul Dhorda, Rob W. van der Pluijm, Arjen M. Dondorp and Phaik Yeong Cheah
Reference: 
Malaria Journal 2021 20:119, 27 February 2021

Malaria remains a major cause of morbidity and mortality in Africa, particularly in children under five years of age. Availability of effective anti-malarial drug treatment is a cornerstone for malaria control and eventual malaria elimination. Artemisinin-based combination therapy (ACT) is worldwide the first-line treatment for uncomplicated falciparum malaria, but the ACT drugs are starting to fail in Southeast Asia because of drug resistance.

Subscribe to RSS - TACT